The oncogenic capacity of this fusion suggests that the activities of these two proteins are related in a way that is physiologically relevant to cancer progression; thus, although not fused in normal development, varied gene dosage due to WHS deletions may have a significant impact on processes lying downstream of both TACC3 and FGFR3 regulation. The gene discussed is TACC3; the disease is cancer.